Linvoseltamab Still Efficacious Despite CRL in Multiple Myeloma: I don't think [the CRL] impacts how I look at the data that [are] publicly available or the long-term approval chances for linvoseltamab and how we might use it in the future," said Surbhi Sidana, MD

Linvoseltamab Still Efficacious Despite CRL in Multiple Myeloma: I don't think [the CRL] impacts how I look at the data that [are] publicly available or the long-term approval chances for linvoseltamab and how we might use it in the future," said Surbhi Sidana, MD

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncology (Williston Park, N.Y.) N.Y.), 2024-10, Vol.38 (10), p.384
1. Verfasser: Sidana, Surbhi
Format: Artikel
Sprache:eng
Schlagworte:
Antibodies
Multiple myeloma
Viral antibodies
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:
ISSN:0890-9091